Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKLIEF vs SOTRADECOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
FDA-approved for the topical treatment of acne vulgaris in patients 9 years of age and older
Uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Small, uncomplicated varicose veins
Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.
0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
Terminal elimination half-life: ~29 hours after topical application; supports once-daily dosing.
Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site
Trifarotene is metabolized primarily via CYP2D6 and to a lesser extent via CYP3A4. It undergoes extensive first-pass metabolism with low systemic exposure after topical application.
Sodium tetradecyl sulfate is primarily metabolized in the liver via sulfation and glucuronidation, with involvement of hepatic enzymes such as sulfotransferases and UDP-glucuronosyltransferases (UGTs).
Fecal: ~70% as unchanged drug; Renal: <1% as metabolites.
Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces
>99% bound to plasma proteins (primarily albumin and lipoproteins).
>90% bound to plasma proteins, primarily albumin
Not determined for topical route; systemic absorption minimal with Vd not clinically relevant.
0.15-0.3 L/kg; reflects limited distribution primarily to plasma and interstitial space
Topical: ~1% systemic absorption; oral: not applicable.
Not applicable; administered via intradermal, intravenous, or endoscopic injection; not intended for oral administration
No dose adjustment required in renal impairment. Not studied in severe renal impairment.
No specific dose adjustment provided in labeling; not studied in renal impairment; use caution in severe impairment.
No dose adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C).
No specific dose adjustment provided in labeling; caution in Child-Pugh class C due to potential for acute hepatic necrosis.
Approved for acne vulgaris in patients aged 12 years and older: apply a thin layer to affected areas once daily in the evening.
Safety and efficacy not established in pediatric patients (age <18 years).
No specific dose adjustment required; clinical studies did not include sufficient geriatric patients to determine differential response.
No specific dose adjustment required; consider comorbidities and overall health status.
None.
Sotradecol injection is contraindicated for the treatment of patients with underlying arterial disease or with known allergy to the drug. Severe adverse reactions including anaphylaxis, pulmonary embolism, and tissue necrosis have been reported.
Local skin reactions (erythema, scaling, dryness, stinging/burning) may occur; reduce frequency or discontinue if severe.,Avoid excessive exposure to sunlight or UV light; use sunscreens and protective clothing.,Avoid contact with eyes, mouth, angles of the nose, and mucous membranes.,Pregnancy: Limited data; no known risk of major malformations based on animal studies, but use only if clearly needed.
Anaphylactic reactions; arterial injection causing tissue necrosis; pulmonary embolism; allergy to the drug; use with caution in patients with thrombophlebitis, hypercoagulable states, or chronic obstructive pulmonary disease; avoid extravasation.
Hypersensitivity to trifarotene or any component of the formulation
Known allergy to sodium tetradecyl sulfate; acute thrombophlebitis; severe chronic venous insufficiency; arterial disease; uncontrolled diabetes mellitus; sepsis; pregnancy; breastfeeding; incompetent perforating veins.
No significant food interactions reported. Avoid excessive alcohol consumption as it may exacerbate skin dryness and irritation. No specific dietary restrictions.
No specific food interactions are known. Patients should maintain adequate hydration and avoid excessive alcohol intake, which may increase the risk of bleeding or thrombosis. No dietary restrictions are required.
Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters: Limited data; avoid unless benefit outweighs risk.
FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third trimester: risk of fetal bradycardia, arrhythmias, or death due to systemic absorption if injected near cervix.
No data on excretion in human milk; M/P ratio unknown. Caution advised due to potential for serious adverse reactions in nursing infants.
Unknown excretion in human milk. Due to low systemic absorption after local injection, risk to breastfed infant is likely low. Caution recommended; M/P ratio not established.
No specific dose adjustments recommended; pharmacokinetic changes in pregnancy unknown. Use lowest effective dose if necessary.
No dose adjustment required; however, use only when clearly needed. Systemic absorption is minimal after local injection, and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety.
AKLIEF (trifarotene) is a fourth-generation retinoid selective for RAR-γ receptors, minimizing irritation compared to tretinoin. Use pea-sized amount for entire face; avoid excessive application. Initiate every other night to improve tolerability. Concomitant use of benzoyl peroxide or salicylic acid may increase dryness; advise non-comedogenic moisturizers. Contraindicated in pregnancy (Category X); rule out pregnancy before starting.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent used for the treatment of varicose veins. Administer via direct injection into the vein using a fine needle; avoid extravasation as it causes tissue necrosis. Perform a test dose (0.5 m L) to assess for hypersensitivity. Compression stockings should be worn for 1-3 weeks post-injection. Do not exceed 10 m L per session; maximum total dose per session is 10 m L of 1% or 2 m L of 3% solution. Use caution in patients with arterial disease, recent thrombosis, or known hypersensitivity. Delayed skin pigmentation may occur. Allergic reactions, including anaphylaxis, have been reported.
Apply a thin layer once daily at night to clean, dry skin.,Avoid sun exposure and use broad-spectrum SPF 30+ sunscreen daily.,May cause initial redness, peeling, and dryness; use moisturizer.,Do not use if pregnant or planning pregnancy; use effective contraception.,Do not apply to cuts, abrasions, or eczematous skin.,Avoid waxing or laser hair removal during treatment.,Therapeutic effect may take 8-12 weeks.,Keep out of reach of children and away from eyes, mouth, and mucous membranes.
This medication is injected directly into your varicose veins to cause them to collapse and fade.,You may experience a burning sensation at the injection site, which is normal.,Wear compression stockings as directed, typically for 1-3 weeks after treatment.,Avoid strenuous exercise and prolonged standing for 24-48 hours after injection.,Contact your doctor if you develop severe pain, swelling, redness, or skin ulcers at the injection site.,Notify your doctor if you have a history of blood clots, allergies, or are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKLIEF vs SOTRADECOL, answered by our medical review team.
AKLIEF is a Topical Retinoid that works by AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.. SOTRADECOL is a Sclerosing agent that works by Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKLIEF and SOTRADECOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKLIEF is: Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.. The standard adult dose of SOTRADECOL is: 0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKLIEF and SOTRADECOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKLIEF is classified as Category C. Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters:. SOTRADECOL is classified as Category C. FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.